NASDAQ:NLNK - NewLink Genetics Stock Price, Forecast & News

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

NewLink Genetics Corp (NASDAQ:NLNK) announced its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative return on equity of 40.06% and a negative net margin of 6,423.69%. View NewLink Genetics' Earnings History.

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for NewLink Genetics.

2 analysts have issued 12-month target prices for NewLink Genetics' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate NewLink Genetics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price. View Analyst Price Targets for NewLink Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.

News headlines about NLNK stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NewLink Genetics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for NewLink Genetics.

NewLink Genetics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,680,000 shares, a decline of 6.7% from the January 15th total of 1,800,000 shares. Based on an average trading volume of 1,088,800 shares, the days-to-cover ratio is presently 1.5 days. Approximately 5.8% of the company's shares are sold short. View NewLink Genetics' Current Options Chain.

Some companies that are related to NewLink Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Opko Health (OPK), SunPower (SPWR), Sarepta Therapeutics (SRPT), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Alibaba Group (BABA) and Cronos Group (CRON).

NewLink Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.38%), Connor Clark & Lunn Investment Management Ltd. (1.00%), Investors Financial Group LLC (0.41%), Requisite Capital Management LLC (0.27%), Jacobs Levy Equity Management Inc. (0.26%) and Oxford Asset Management LLP (0.23%). View Institutional Ownership Trends for NewLink Genetics.

NLNK stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Acadian Asset Management LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for NewLink Genetics.

NLNK stock was purchased by a variety of institutional investors in the last quarter, including Investors Financial Group LLC, Jacobs Levy Equity Management Inc., Requisite Capital Management LLC, Jane Street Group LLC, Cambridge Investment Research Advisors Inc. and Ladenburg Thalmann Financial Services Inc.. View Insider Buying and Selling for NewLink Genetics.

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NLNK stock can currently be purchased for approximately $1.58.

NewLink Genetics has a market capitalization of $58.98 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.View Additional Information About NewLink Genetics.

The official website for NewLink Genetics is http://www.newlinkgenetics.com/.

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]